漢康生技 - HanchorBio - 創新、卓越、高效

創新驅動生命希望照亮未來

Innovating for Life, Inspiring Hope

Our Possibility

我們的可能性

研發專案

                                                                8
                                +
                            

專利申請

                                                                100
                                +
                            

進入臨床IND階段

最快

                                                                2.3
                                年
                            

2024年的研發投資金額

                                                                7.89
                                億元
                            

FBDB™

技術平台的核心優勢

結合先天性及適應性免疫系統多管齊下攻擊腫瘤細胞
阻斷 SIRPα / CD47 訊號傳遞
阻斷 PD-1 / PD-L1訊號傳遞
改善腫瘤微環境或進一步激活巨噬細胞/T細胞

更多核心技術

News

最新消息

HanchorBio-Selects-Bloomberg-to-Strengthen-its-Strategic-Intelligence-Across-Drug-Development-and-Global-Biopharma

漢康生技與彭博合作強化藥物開發及全球生物製藥戰略情報能力 HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma

HanchorBio announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.

4 月 24, 2026

漢康生技於GBCC 2026發表HCB101聯合療法一線三陰性乳癌早期數據HanchorBio Presents Early Frontline Triple-Negative Breast Cancer Data for HCB101 Combination at GBCC 2026

HanchorBio announced the first dedicated presentation of HCB101 clinical data from an ongoing study evaluating HCB101 in combination with anti-PD-1 and nab-paclitaxel in patients with advanced triple-negative breast cancer (TNBC) at the Global Breast Cancer Conference 2026 (GBCC 2026) in Seoul, Korea.

4 月 23, 2026

漢康生技發布 HCB101 頭頸癌數據：單藥展現持久活性，低劑量聯合 PD-1 觀察到完全緩解 HanchorBio Reports Head and Neck Cancer Data for HCB101, Including Durable Monotherapy Activity and Complete Response at Low Dose in Combination with PD-1

HanchorBio reported updated clinical observations in head and neck squamous cell carcinoma (HNSCC) across both monotherapy and combination settings for HCB101, its rationally engineered SIRPα-Fc fusion protein functioning as an innate immune checkpoint blockade.

4 月 22, 2026

漢康生技報告2026年上半年科學溝通成果，並預告第二季將參與多項學術會議HanchorBio Reports Strong H1 2026 Scientific Communication Momentum and Highlights Upcoming Q2 Conference Participation

HanchorBio announced strong scientific communication momentum in the first half of 2026, marked by a broad series of oral, mini-oral, symposium, keynote, and poster presentations across major international scientific meetings. The Company also highlighted its upcoming and recently accepted conference participation in Q2 2026, underscoring continued external visibility across multiple programs, disease areas, and translational settings.

4 月 20, 2026

漢康生技宣布 HCB101 完成首次 2,000 公升臨床用藥 GMP 批次生產 HanchorBio Announces Successful Completion of First 2,000L GMP Clinical Batch Production of HCB101

HanchorBio's HCB101, one of its core FBDB™ (Fc-Based Designer Biologics) oncology pipeline assets, has successfully completed its first GMP clinical batch production scaled up from a 500L to a 2,000L bioreactor. This production was carried out at WuXi Biologics’ manufacturing facility, covering the full process from Drug Substance (DS) to Drug Product (DP), and achieved all predefined manufacturing objectives.

4 月 14, 2026

漢康生技受邀參加寬量國際主辦第十九屆 CEO Week 投資論壇 HanchorBio Invited to Participate in the 19th QIC CEO Week

HanchorBio has been invited to participate in the 19th QIC CEO Week to meet with international institutional investors in Singapore to share corporate progress and strategic priorities.

4 月 13, 2026

漢康生技 HCB301 於台灣完成第一期臨床試驗首位患者給藥HanchorBio Doses First Patient in Taiwan in Phase 1 Trial of HCB301

HanchorBio today announced that the first patient in Taiwan has been dosed in HCB301-101, the Company’s ongoing first-in-human Phase 1 clinical study of HCB301.

4 月 08, 2026

HanchorBio Signals “Backbone” Potential for HCB101 as SAB Aligns on Gastric Cancer Registrational Path隨著科學顧問委員會（SAB）就胃癌藥證註冊路徑達成共識，漢康生技釋出 HCB101 具備「治療骨幹療法」潛力的明確訊號

HanchorBio reported outcomes from its recent Scientific Advisory Board (SAB) meeting, highlighting a shift from platform validation to asset-level positioning and registrational strategy.

4 月 03, 2026

HanchorBio Reports Early Taiwan IIT Signal in 2L CRC With Sustained Disease Control Beyond 37 Weeks漢康生技公布台灣研究者發起的臨床研究於二線大腸直腸癌之早期訊號，疾病控制可持續超過 37 週

HanchorBio today announced early findings from an ongoing investigator-initiated trial (IIT) in Taiwan evaluating HCB101-based combination therapy in patients with second-line colorectal cancer (CRC).

4 月 03, 2026

HanchorBio Reports Preliminary First-Line HER2+ Gastric Cancer Data for HCB101, Demonstrating 83.3% ORR漢康生技公布HCB101 HER2陽性胃癌一線治療初步數據 ORR達 83.3%

Hanchorbio's preliminary clinical observations from its ongoing Phase 1b/2a study evaluating HCB101-based combination therapy in first-line HER2-positive gastric cancer.

4 月 01, 2026